Skip to content
2000
image of Unveiling the Healing Potential of Stem Cells: The Promising Role of Secretome Therapy in the Treatment of Pulmonary Degenerative Disorders-A Comprehensive Systematic Review

Abstract

Background and Objective

Stem cell-based therapy has emerged as a promising avenue for treating pulmonary degenerative disorders due to its remarkable capacity for self-renewal and differentiation into various cell types. However, concerns regarding undesired differentiation and tumorigenicity have raised questions about the safety and efficacy of cell-based therapy. The aim of the present systematic review study was to determine the therapeutic effectiveness of stem cell secretome in mitigating three pulmonary degenerative diseases, including Acute Lung Injury (ALI), Idiopathic Pulmonary Fibrosis (IPF), and Bronchopulmonary Dysplasia (BPD).

Method

A comprehensive search was carried out on international databases, including MEDLINE, Scopus, Web of Science, PubMed, and Embase, using related keywords according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA-2020) guidelines.

Results

Of 1541 retrieved studies, 136 articles were included in the present systematic review. The therapeutic effects of stem cells are primarily attributed to their paracrine secretions, specifically bioactive molecules known as the secretome, which includes exosomes and extracellular vesicles. Secretome-based therapy shows great promise in maximizing the healing potential of stem cells. However, several challenges and limitations hinder its widespread application, including scalability issues, delivery challenges, difficulty in controlling dosage, and the lack of standardized production protocols. As it is a novel therapeutic approach, its complex composition, mechanism of action, and variability in responses from the body, as well as long-term safety, remain unknown and pose challenges that necessitate further investigation and well-designed clinical trials.

Conclusion

The secretome exerts its protective and therapeutic effects by regulating various processes, including inflammation, oxidative stress, cell apoptosis, macrophage polarization, growth factor signaling pathways, immune cell activation, TGF-β signaling pathways, angiogenesis, structural attenuation, fibrosis resolution, pulmonary functional improvement, and alveolarization.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cscr/10.2174/011574888X373765250710105821
2025-07-22
2026-02-27

  • From This Site

    /content/journals/cscr/10.2174/011574888X373765250710105821
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Xia C. Dai Z. Jin Y. Chen P. Emerging antioxidant paradigm of mesenchymal stem cell-derived exosome therapy. Front. Endocrinol. 2021 12 727272 10.3389/fendo.2021.727272 34912294
    [Google Scholar]
  2. Stavely R. Nurgali K. The emerging antioxidant paradigm of mesenchymal stem cell therapy. Stem Cells Transl. Med. 2020 9 9 985 1006 10.1002/sctm.19‑0446 32497410
    [Google Scholar]
  3. Phinney D.G. Pittenger M.F. Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells 2017 35 4 851 858 10.1002/stem.2575 28294454
    [Google Scholar]
  4. de Girolamo L. Lucarelli E. Alessandri G. Mesenchymal stem/stromal cells: A new “cells as drugs” paradigm. Efficacy and critical aspects in cell therapy. Curr. Pharm. Des. 2013 19 13 2459 2473 10.2174/1381612811319130015 23278600
    [Google Scholar]
  5. Kudlik G. Hegyi B. Czibula Á. Monostori É. Buday L. Uher F. Mesenchymal stem cells promote macrophage polarization toward M2b-like cells. Exp. Cell Res. 2016 348 1 36 45 10.1016/j.yexcr.2016.08.022 27578361
    [Google Scholar]
  6. Caplan A.I. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J. Cell. Physiol. 2007 213 2 341 347 10.1002/jcp.21200 17620285
    [Google Scholar]
  7. Caplan A.I. Review: Mesenchymal stem cells: Cell-based reconstructive therapy in orthopedics. Tissue Eng. 2005 11 7-8 1198 1211 10.1089/ten.2005.11.1198 16144456
    [Google Scholar]
  8. Caplan A.I. Dennis J.E. Mesenchymal stem cells as trophic mediators. J. Cell. Biochem. 2006 98 5 1076 1084 10.1002/jcb.20886 16619257
    [Google Scholar]
  9. Kosaric N. Srifa W. Bonham C.A. Macrophage subpopulation dynamics shift following intravenous infusion of mesenchymal stromal cells. Mol. Ther. 2020 28 9 2007 2022 10.1016/j.ymthe.2020.05.022 32531238
    [Google Scholar]
  10. Nakazaki M. Morita T. Lankford K.L. Askenase P.W. Kocsis J.D. Small extracellular vesicles released by infused mesenchymal stromal cells target M2 macrophages and promote TGF‐β upregulation, microvascular stabilization and functional recovery in a rodent model of severe spinal cord injury. J. Extracell. Vesicles 2021 10 11 12137 10.1002/jev2.12137 34478241
    [Google Scholar]
  11. Wangler S. Kamali A. Wapp C. Uncovering the secretome of mesenchymal stromal cells exposed to healthy, traumatic, and degenerative intervertebral discs: A proteomic analysis. Stem Cell Res. Ther. 2021 12 1 11 10.1186/s13287‑020‑02062‑2 33413584
    [Google Scholar]
  12. Vizoso F. Eiro N. Cid S. Schneider J. Perez-Fernandez R. Mesenchymal stem cell secretome: Toward cell-free therapeutic strategies in regenerative medicine. Int. J. Mol. Sci. 2017 18 9 1852 10.3390/ijms18091852 28841158
    [Google Scholar]
  13. Hu W. Yang J. Xue J. Secretome of hESC-derived MSC-like immune and matrix regulatory cells mitigate pulmonary fibrosis through antioxidant and anti-inflammatory effects. Biomedicines 2023 11 2 463 10.3390/biomedicines11020463 36830999
    [Google Scholar]
  14. Rafei M. Campeau P.M. Aguilar-Mahecha A. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J. Immunol. 2009 182 10 5994 6002 10.4049/jimmunol.0803962 19414750
    [Google Scholar]
  15. Kim H.S. Shin T.H. Lee B.C. Human umbilical cord blood mesenchymal stem cells reduce colitis in mice by activating NOD2 signaling to COX2. Gastroenterology 2013 145 6 1392 1403 10.1053/j.gastro.2013.08.033
    [Google Scholar]
  16. Page M.J. McKenzie J.E. Bossuyt P.M. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021 372 n71 10.1136/bmj.n71
    [Google Scholar]
  17. Bogatcheva N.V. Coleman M.E. Concentrated secretome of adipose stromal cells limits influenza A virus-induced lung injury in mice. Cells 2021 10 4 720 10.3390/cells10040720 33804896
    [Google Scholar]
  18. Epstein Shochet G. Brook E. Bardenstein-Wald B. Shitrit D. TGF-β pathway activation by idiopathic pulmonary fibrosis (IPF) fibroblast derived soluble factors is mediated by IL-6 trans-signaling. Respir. Res. 2020 21 1 56 10.1186/s12931‑020‑1319‑0 32070329
    [Google Scholar]
  19. Fernandez I.E. Eickelberg O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet 2012 380 9842 680 688 10.1016/S0140‑6736(12)61144‑1 22901889
    [Google Scholar]
  20. Fu R. Li Q. Fan R. iTRAQ-based secretome reveals that SiO2 induces the polarization of RAW264.7 macrophages by activation of the NOD-RIP2-NF-κB signaling pathway. Environ. Toxicol. Pharmacol. 2018 63 92 102 10.1016/j.etap.2018.08.010 30189374
    [Google Scholar]
  21. Grommes J. Soehnlein O. Contribution of neutrophils to acute lung injury. Mol. Med. 2011 17 3-4 293 307 10.2119/molmed.2010.00138 21046059
    [Google Scholar]
  22. Sankari A. Chapman K. Ullah S. Idiopathic pulmonary fibrosis. In: StatPearls. Treasure Island, Florida 2024
    [Google Scholar]
  23. Jobe A.H. The new bronchopulmonary dysplasia. Curr. Opin. Pediatr. 2011 23 2 167 172 10.1097/MOP.0b013e3283423e6b 21169836
    [Google Scholar]
  24. Kim S.J. Kang N. Joo H. Park C. Kim Y.K. P3.01-057 TGF-β Induced EMT and Stemness Characteristics in Lung Cancer. J. Thorac. Oncol. 2017 12 1 S1154 S1155 10.1016/j.jtho.2016.11.1623
    [Google Scholar]
  25. Kwinta P. Bik-Multanowski M. Mitkowska Z. Tomasik T. Legutko M. Pietrzyk J.J. Genetic risk factors of bronchopulmonary dysplasia. Pediatr. Res. 2008 64 6 682 688 10.1203/PDR.0b013e318184edeb 18614962
    [Google Scholar]
  26. Liu T. Zhang L. Joo D. Sun S-C. NF-κB signaling in inflammation. Signal Transduct. Target. Ther. 2017 2 1 9
    [Google Scholar]
  27. Liu Y.C. Zou X.B. Chai Y.F. Yao Y.M. Macrophage polarization in inflammatory diseases. Int. J. Biol. Sci. 2014 10 5 520 529 10.7150/ijbs.8879 24910531
    [Google Scholar]
  28. Mandal P.K. Roy R.G. Samkaria A. Oxidative stress: Glutathione and its potential to protect methionine-35 of Aβ peptide from oxidation. ACS Omega 2022 7 31 27052 27061 10.1021/acsomega.2c02760 35967059
    [Google Scholar]
  29. Mariduena J. Ramagopal M. Hiatt M. Chandra S. Laumbach R. Hegyi T. Vascular endothelial growth factor levels and bronchopulmonary dysplasia in preterm infants. J. Matern. Fetal Neonatal Med. 2022 35 8 1517 1522 10.1080/14767058.2020.1760826 32366142
    [Google Scholar]
  30. Mathew R. Signaling pathways involved in the development of bronchopulmonary dysplasia and pulmonary hypertension. Children 2020 7 8 100 10.3390/children7080100 32824651
    [Google Scholar]
  31. Aoudjehane L. Pissaia A. Scatton O. Interleukin-4 induces the activation and collagen production of cultured human intrahepatic fibroblasts via the STAT-6 pathway. Lab. Invest. 2008 88 9 973 985 10.1038/labinvest.2008.61 18626468
    [Google Scholar]
  32. Mora A.L. Rojas M. Aging and lung injury repair: A role for bone marrow derived mesenchymal stem cells. J. Cell. Biochem. 2008 105 3 641 647 10.1002/jcb.21890 18759327
    [Google Scholar]
  33. Morrow L.A. Wagner B.D. Ingram D.A. Antenatal determinants of bronchopulmonary dysplasia and late respiratory disease in preterm infants. Am. J. Respir. Crit. Care Med. 2017 196 3 364 374 10.1164/rccm.201612‑2414OC 28249118
    [Google Scholar]
  34. Myllärniemi M. Kaarteenaho R. Pharmacological treatment of idiopathic pulmonary fibrosis – preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine. Eur. Clin. Respir. J. 2015 2 1 26385 10.3402/ecrj.v2.26385 26557253
    [Google Scholar]
  35. Nakanishi H. Uchiyama A. Kusuda S. Impact of pulmonary hypertension on neurodevelopmental outcome in preterm infants with bronchopulmonary dysplasia: A cohort study. J. Perinatol. 2016 36 10 890 896 10.1038/jp.2016.108 27442157
    [Google Scholar]
  36. Nathan S.D. Shlobin O.A. Weir N. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011 140 1 221 229 10.1378/chest.10‑2572 21729893
    [Google Scholar]
  37. Zhang J. Guo Y. Mak M. Tao Z. Translational medicine for acute lung injury. J. Transl. Med. 2024 22 1 25 10.1186/s12967‑023‑04828‑7 38183140
    [Google Scholar]
  38. Oak P. Pritzke T. Thiel I. Attenuated PDGF signaling drives alveolar and microvascular defects in neonatal chronic lung disease. EMBO Mol. Med. 2017 9 11 1504 1520 10.15252/emmm.201607308 28923828
    [Google Scholar]
  39. Oh W. Poindexter B.B. Perritt R. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants. J. Pediatr. 2005 147 6 786 790 10.1016/j.jpeds.2005.06.039 16356432
    [Google Scholar]
  40. Osman A. Chittiboyina A. Khan I. Cytoprotective role of dietary phytochemicals against cancer development via induction of phase II and antioxidant enzymes. In: Adv Mol Toxicol. Amsterdam, Netherlands Elsevier 2016 10 99 137 10.1016/B978‑0‑12‑804700‑2.00003‑9
    [Google Scholar]
  41. Parameswaran N. Patial S. Tumor necrosis factor-α signaling in macrophages. Crit. Rev. Eukaryot. Gene Exp. 2010 20 2 87 103 10.1615/critreveukargeneexpr.v20.i2.10
    [Google Scholar]
  42. Peng W. Chang M. Wu Y. Lyophilized powder of mesenchymal stem cell supernatant attenuates acute lung injury through the IL-6–p-STAT3–p63–JAG2 pathway. Stem Cell Res. Ther. 2021 12 1 216 10.1186/s13287‑021‑02276‑y 33781349
    [Google Scholar]
  43. Phua J. Badia J.R. Adhikari N.K.J. Has mortality from acute respiratory distress syndrome decreased over time?: A systematic review. Am. J. Respir. Crit. Care Med. 2009 179 3 220 227 10.1164/rccm.200805‑722OC 19011152
    [Google Scholar]
  44. Poon A.W.H. Ma E.X.H. Vadivel A. Impact of bronchopulmonary dysplasia on brain and retina. Biol. Open 2016 5 4 475 483 10.1242/bio.017665 26988760
    [Google Scholar]
  45. Porzionato A. Zaramella P. Dedja A. Intratracheal administration of mesenchymal stem cell-derived extracellular vesicles reduces lung injuries in a chronic rat model of bronchopulmonary dysplasia. Am. J. Physiol. Lung Cell. Mol. Physiol. 2021 320 5 L688 L704 10.1152/ajplung.00148.2020 33502939
    [Google Scholar]
  46. Raghu G. Idiopathic pulmonary fibrosis: Guidelines for diagnosis and clinical management have advanced from consensus-based in 2000 to evidence-based in 2011. Eur. Respir. J. 2011 37 4 743 746 10.1183/09031936.00017711 21454891
    [Google Scholar]
  47. Richeldi L. du Bois R.M. Raghu G. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014 370 22 2071 2082 10.1056/NEJMoa1402584 24836310
    [Google Scholar]
  48. Rubenfeld G.D. Caldwell E. Peabody E. Incidence and outcomes of acute lung injury. N. Engl. J. Med. 2005 353 16 1685 1693 10.1056/NEJMoa050333 16236739
    [Google Scholar]
  49. Saguil A. Fargo M. Acute respiratory distress syndrome: Diagnosis and management. Am. Fam. Physician 2012 85 4 352 358 22335314
    [Google Scholar]
  50. Serrano-Gomez S.J. Maziveyi M. Alahari S.K. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol. Cancer 2016 15 1 18 10.1186/s12943‑016‑0502‑x 26905733
    [Google Scholar]
  51. She Y.X. Yu Q.Y. Tang X.X. Role of interleukins in the pathogenesis of pulmonary fibrosis. Cell Death Discov. 2021 7 1 52 10.1038/s41420‑021‑00437‑9 33723241
    [Google Scholar]
  52. Shenderov K. Collins S.L. Powell J.D. Horton M.R. Immune dysregulation as a driver of idiopathic pulmonary fibrosis. J. Clin. Invest. 2021 131 2 143226 10.1172/JCI143226 33463535
    [Google Scholar]
  53. Silva-Filho J.L. Caruso-Neves C. Pinheiro A.A.S. IL-4: An important cytokine in determining the fate of T cells. Biophys. Rev. 2014 6 1 111 118 10.1007/s12551‑013‑0133‑z 28509961
    [Google Scholar]
  54. Singh S Anshita D Ravichandiran V. MCP-1: Function, regulation, and involvement in disease. Int Immunopharmacol 2021 101 Pt B107598 10.1016/j.intimp.2021.107598 34233864
    [Google Scholar]
  55. Soomro S. Oxidative stress and inflammation. Open J. Immunol. 2019 9 1 1 20 10.4236/oji.2019.91001
    [Google Scholar]
  56. Spagnolo P. Sverzellati N. Rossi G. Idiopathic pulmonary fibrosis: An update. Ann. Med. 2015 47 1 15 27 10.3109/07853890.2014.982165 25613170
    [Google Scholar]
  57. Spinelli E. Mauri T. Beitler J.R. Pesenti A. Brodie D. Respiratory drive in the acute respiratory distress syndrome: Pathophysiology, monitoring, and therapeutic interventions. Intensive Care Med. 2020 46 4 606 618 10.1007/s00134‑020‑05942‑6 32016537
    [Google Scholar]
  58. Stoll B.J. Hansen N.I. Bell E.F. Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993-2012. JAMA 2015 314 10 1039 1051 10.1001/jama.2015.10244 26348753
    [Google Scholar]
  59. Sun Z. Su Z. Zhou Z. RNA demethylase ALKBH5 inhibits TGF‐β‐induced EMT by regulating TGF‐β/SMAD signaling in non‐small cell lung cancer. FASEB J. 2022 36 5 22283 10.1096/fj.202200005RR 35344216
    [Google Scholar]
  60. Tan J. Zhuo Z. Wang X. Zhang Y. Qian Y. Lin F. Secretome of EMSCs neutralizes LPS induced acute lung injury via aerosol administration. Int. J. Mol. Med. 2023 52 5 104 10.3892/ijmm.2023.5307 37772372
    [Google Scholar]
  61. Thébaud B. Goss K.N. Laughon M. Bronchopulmonary dysplasia. Nat. Rev. Dis. Primers 2019 5 1 78 10.1038/s41572‑019‑0127‑7 31727986
    [Google Scholar]
  62. Theocharis A.D. Skandalis S.S. Gialeli C. Karamanos N.K. Extracellular matrix structure. Adv. Drug Deliv. Rev. 2016 97 4 27 10.1016/j.addr.2015.11.001 26562801
    [Google Scholar]
  63. Trembath A. Laughon M.M. Predictors of bronchopulmonary dysplasia. Clin. Perinatol. 2012 39 3 585 601 10.1016/j.clp.2012.06.014 22954271
    [Google Scholar]
  64. Valencia A.M. Abrantes M.A. Hasan J. Aranda J.V. Beharry K.D. Reactive oxygen species, biomarkers of microvascular maturation and alveolarization, and antioxidants in oxidative lung injury. React. Oxyg. Species (Apex) 2018 6 18 373 388 30533532
    [Google Scholar]
  65. Vallée A. Lecarpentier Y. TGF-β in fibrosis by acting as a conductor for contractile properties of myofibroblasts. Cell Biosci. 2019 9 1 98 10.1186/s13578‑019‑0362‑3 31827764
    [Google Scholar]
  66. Villar J. Blanco J. Kacmarek R.M. Current incidence and outcome of the acute respiratory distress syndrome. Curr. Opin. Crit. Care 2016 22 1 1 6 10.1097/MCC.0000000000000266 26645551
    [Google Scholar]
  67. Vohr B.R. Wright L.L. Poole W.K. McDonald S.A. Pediatrics 2005 116 3 635 643 10.1542/peds.2004‑2247 16143580
    [Google Scholar]
  68. Walter J. Ware L.B. Matthay M.A. Mesenchymal stem cells: Mechanisms of potential therapeutic benefit in ARDS and sepsis. Lancet Respir. Med. 2014 2 12 1016 1026 10.1016/S2213‑2600(14)70217‑6 25465643
    [Google Scholar]
  69. Wheeler A.P. Bernard G.R. Acute lung injury and the acute respiratory distress syndrome: A clinical review. Lancet 2007 369 9572 1553 1564 10.1016/S0140‑6736(07)60604‑7 17482987
    [Google Scholar]
  70. Wight T.N. Potter-Perigo S. The extracellular matrix: An active or passive player in fibrosis? Am. J. Physiol. Gastrointest. Liver Physiol. 2011 301 6 G950 G955 10.1152/ajpgi.00132.2011 21512158
    [Google Scholar]
  71. Willis G.R. Fernandez-Gonzalez A. Anastas J. Mesenchymal stromal cell exosomes ameliorate experimental bronchopulmonary dysplasia and restore lung function through macrophage immunomodulation. Am. J. Respir. Crit. Care Med. 2018 197 1 104 116 10.1164/rccm.201705‑0925OC 28853608
    [Google Scholar]
  72. Willis G.R. Fernandez-Gonzalez A. Reis M. Mesenchymal stromal cell‐derived small extracellular vesicles restore lung architecture and improve exercise capacity in a model of neonatal hyperoxia‐induced lung injury. J. Extracell. Vesicles 2020 9 1 1790874 10.1080/20013078.2020.1790874 32939235
    [Google Scholar]
  73. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008 214 2 199 210 10.1002/path.2277 18161745
    [Google Scholar]
  74. Xu Z. Lin L. Fan Y. Secretome of mesenchymal stem cells from consecutive hypoxic cultures promotes resolution of lung inflammation by reprogramming anti-inflammatory macrophages. Int. J. Mol. Sci. 2022 23 8 4333 10.3390/ijms23084333 35457151
    [Google Scholar]
  75. Yang D. Chen X. Wang J. Dysregulated lung commensal bacteria drive interleukin-17B production to promote pulmonary fibrosis through their outer membrane vesicles. Immunity 2019 50 3 692 706 10.1016/j.immuni.2019.02.001
    [Google Scholar]
  76. Younge N. Goldstein R.F. Bann C.M. Survival and neurodevelopmental outcomes among periviable infants. N. Engl. J. Med. 2017 376 7 617 628 10.1056/NEJMoa1605566 28199816
    [Google Scholar]
  77. Yu T. Cui Y. Xin S. Mesenchymal stem cell conditioned medium alleviates acute lung injury through KGF-mediated regulation of epithelial sodium channels. Biomed. Pharmacother. 2023 169 115896 10.1016/j.biopha.2023.115896 37984305
    [Google Scholar]
  78. Zank D.C. Bueno M. Mora A.L. Rojas M. Idiopathic pulmonary fibrosis: Aging, mitochondrial dysfunction, and cellular bioenergetics. Front. Med. 2018 5 10 10.3389/fmed.2018.00010 29459894
    [Google Scholar]
  79. Zhao Y.A.L.E.I. Zhu R.T. Sun Y.L. Epithelial-mesenchymal transition in liver fibrosis. Biomed. Rep. 2016 4 3 269 274 10.3892/br.2016.578 26998262
    [Google Scholar]
  80. Zhu X. Wang B. Zhang X. Alpha-linolenic acid protects against lipopolysaccharide-induced acute lung injury through anti-inflammatory and anti-oxidative pathways. Microb. Pathog. 2020 142 104077 10.1016/j.micpath.2020.104077 32084579
    [Google Scholar]
  81. Ambalavanan N. Van Meurs K.P. Perritt R. Predictors of death or bronchopulmonary dysplasia in preterm infants with respiratory failure. J. Perinatol. 2008 28 6 420 426 10.1038/jp.2008.18 18337740
    [Google Scholar]
  82. Atanasova E. Milosevic D. Bornschlegl S. Normal ex vivo mesenchymal stem cell function combined with abnormal immune profiles sets the stage for informative cell therapy trials in idiopathic pulmonary fibrosis patients. Stem Cell Res. Ther. 2022 13 1 45 10.1186/s13287‑021‑02692‑0 35101101
    [Google Scholar]
  83. Bandeira E. Oliveira H. Silva J.D. Therapeutic effects of adipose-tissue-derived mesenchymal stromal cells and their extracellular vesicles in experimental silicosis. Respir. Res. 2018 19 1 104 10.1186/s12931‑018‑0802‑3 29843724
    [Google Scholar]
  84. Barkauskas C.E. Noble P.W. Cellular mechanisms of tissue fibrosis. 7. new insights into the cellular mechanisms of pulmonary fibrosis. Am. J. Physiol. Cell Physiol. 2014 306 11 C987 C996 10.1152/ajpcell.00321.2013 24740535
    [Google Scholar]
  85. Betensley A. Sharif R. Karamichos D. A systematic review of the role of dysfunctional wound healing in the pathogenesis and treatment of idiopathic pulmonary fibrosis. J. Clin. Med. 2016 6 1 2 10.3390/jcm6010002 28035951
    [Google Scholar]
  86. Bringardner B.D. Baran C.P. Eubank T.D. Marsh C.B. The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxid. Redox Signal. 2008 10 2 287 302 10.1089/ars.2007.1897 17961066
    [Google Scholar]
  87. Capasso L. Vento G. Loddo C. Oxidative stress and bronchopulmonary dysplasia: Evidences from microbiomics, metabolomics, and proteomics. Front Pediatr. 2019 7 30 10.3389/fped.2019.00030 30815432
    [Google Scholar]
  88. Chakraborti S. Sarkar J. Pramanik P.K. Chakraborti T. Role of proteases in lung disease: A brief overview. Prot Human Dis 2017 333 374 10.1007/978‑981‑10‑3162‑5_16
    [Google Scholar]
  89. Chen C.Y. Rao S.S. Ren L. Exosomal DMBT1 from human urine-derived stem cells facilitates diabetic wound repair by promoting angiogenesis. Theranostics 2018 8 6 1607 1623 10.7150/thno.22958
    [Google Scholar]
  90. Chilosi M. Carloni A. Rossi A. Poletti V. Premature lung aging and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis and COPD/emphysema. Transl. Res. 2013 162 3 156 173 10.1016/j.trsl.2013.06.004 23831269
    [Google Scholar]
  91. Dushianthan A. Grocott M.P.W. Postle A.D. Cusack R. Acute respiratory distress syndrome and acute lung injury. Postgrad. Med. J. 2011 87 1031 612 622 10.1136/pgmj.2011.118398 21642654
    [Google Scholar]
  92. Fois A.G. Paliogiannis P. Sotgia S. Evaluation of oxidative stress biomarkers in idiopathic pulmonary fibrosis and therapeutic applications: A systematic review. Respir. Res. 2018 19 1 51 10.1186/s12931‑018‑0754‑7 29587761
    [Google Scholar]
  93. Giebel B. Kordelas L. Börger V. Clinical potential of mesenchymal stem/stromal cell-derived extracellular vesicles. Stem Cell Investig. 2017 4 10 84 10.21037/sci.2017.09.06 29167805
    [Google Scholar]
  94. Gimona M. Pachler K. Laner-Plamberger S. Schallmoser K. Rohde E. Manufacturing of human extracellular vesicle-based therapeutics for clinical use. Int. J. Mol. Sci. 2017 18 6 1190 10.3390/ijms18061190 28587212
    [Google Scholar]
  95. Sankari A. Chapman K. Ullah S. Idiopathic Pulmonary Fibrosis. In: StatPearls, StatPearls Publishing Copyright © 2025. StatPearls Publishing LLC 2025
    [Google Scholar]
  96. Hayes D. Feola D.J. Murphy B.S. Shook L.A. Ballard H.O. Pathogenesis of bronchopulmonary dysplasia. Respiration 2010 79 5 425 436 10.1159/000242497 19786727
    [Google Scholar]
  97. Hezam K. Wang C. Fu E. Superior protective effects of PGE2 priming mesenchymal stem cells against LPS-induced acute lung injury (ALI) through macrophage immunomodulation. Stem Cell Res. Ther. 2023 14 1 48 10.1186/s13287‑023‑03277‑9 36949464
    [Google Scholar]
  98. Jobe A.H. Bancalari E. Bronchopulmonary dysplasia. Am. J. Respir. Crit. Care Med. 2001 163 7 1723 1729 10.1164/ajrccm.163.7.2011060 11401896
    [Google Scholar]
  99. Johnson E.R. Matthay M.A. Acute lung injury: Epidemiology, pathogenesis, and treatment. J. Aerosol Med. Pulm. Drug Deliv. 2010 23 4 243 252 10.1089/jamp.2009.0775 20073554
    [Google Scholar]
  100. Kaur A. Mathai S.K. Schwartz D.A. Genetics in idiopathic pulmonary fibrosis pathogenesis, prognosis, and treatment. Front. Med. 2017 4 154 10.3389/fmed.2017.00154 28993806
    [Google Scholar]
  101. Keszler M. Sant’Anna G. Mechanical ventilation and bronchopulmonary dysplasia. Clin. Perinatol. 2015 42 4 781 796 10.1016/j.clp.2015.08.006 26593078
    [Google Scholar]
  102. King T.E. Bradford W.Z. Castro-Bernardini S. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014 370 22 2083 2092 10.1056/NEJMoa1402582 24836312
    [Google Scholar]
  103. Kudinov V.A. Artyushev R.I. Zurina I.M. Inhaled placental mesenchymal stromal cell secretome from two-and three-dimensional cell cultures promotes survival and regeneration in acute lung injury model in mice. Int. J. Mol. Sci. 2022 23 7 3417 10.3390/ijms23073417 35408778
    [Google Scholar]
  104. Laffey J.G. Matthay M.A. Fifty years of research in ARDS. Cell-based therapy for acute respiratory distress syndrome. Biology and potential therapeutic value. Am. J. Respir. Crit. Care Med. 2017 196 3 266 273 10.1164/rccm.201701‑0107CP 28306336
    [Google Scholar]
  105. Ley B. Ryerson C.J. Vittinghoff E. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann. Intern. Med. 2012 156 10 684 691 10.7326/0003‑4819‑156‑10‑201205150‑00004 22586007
    [Google Scholar]
  106. Herrero R. Sanchez G. Lorente J.A. New insights into the mechanisms of pulmonary edema in acute lung injury. Ann. Transl. Med. 2018 6 2 32 10.21037/atm.2017.12.18 29430449
    [Google Scholar]
  107. Cerri S. Monari M. Guerrieri A. Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment. Respir. Med. 2019 159 105803 10.1016/j.rmed.2019.105803 31670147
    [Google Scholar]
  108. Mirsanei Z. Jamshidi-Adegani F. Ahangari F. Soufihasanabad S. Soudi S. Inhalation of Mesenchymal Stem Cell-Derived Small Extracellular Vesicles as a Possible Approach to Ameliorating Acute Lung Injury Caused by Cytokine Storm. Stud Rese Transl Med 2024 6 44112
    [Google Scholar]
  109. Kolb M. Margetts P.J. Anthony D.C. Pitossi F. Gauldie J. Transient expression of IL-1β induces acute lung injury and chronic repair leading to pulmonary fibrosis. J. Clin. Invest. 2001 107 12 1529 1536 10.1172/JCI12568 11413160
    [Google Scholar]
  110. Goldman J.L. Sammani S. Kempf C. Pleiotropic effects of interleukin-6 in a “two-hit” murine model of acute respiratory distress syndrome. Pulm. Circ. 2014 4 2 280 288 10.1086/675991 25006447
    [Google Scholar]
  111. Desai O. Winkler J. Minasyan M. Herzog E.L. The role of immune and inflammatory cells in idiopathic pulmonary fibrosis. Front. Med. 2018 5 43 10.3389/fmed.2018.00043 29616220
    [Google Scholar]
  112. Dinh P.U.C. Paudel D. Brochu H. Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis. Nat. Commun. 2020 11 1 1064 10.1038/s41467‑020‑14344‑7 32111836
    [Google Scholar]
  113. Frangogiannis N.G. Transforming growth factor–β in tissue fibrosis. J. Exp. Med. 2020 217 3 20190103 10.1084/jem.20190103 32997468
    [Google Scholar]
  114. Lijnen P. Petrov V. Transforming growth factor-beta 1-induced collagen production in cultures of cardiac fibroblasts is the result of the appearance of myofibroblasts. Methods Find. Exp. Clin. Pharmacol. 2002 24 6 333 344 10.1358/mf.2002.24.6.693065 12224439
    [Google Scholar]
  115. Itoigawa Y. Harada N. Harada S. TWEAK enhances TGF-β-induced epithelial-mesenchymal transition in human bronchial epithelial cells. Respir. Res. 2015 16 1 48 10.1186/s12931‑015‑0207‑5 25890309
    [Google Scholar]
  116. Hussain T. Tan B. Yin Y. Blachier F. Tossou M.C. Rahu N. Oxidative stress and inflammation: What polyphenols can do for us? Oxidat Med. Cell. Long. 2016 2016 7432797 10.1155/2016/7432797
    [Google Scholar]
  117. Jang D. Lee A.H. Shin H.Y. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics. Int. J. Mol. Sci. 2021 22 5 2719 10.3390/ijms22052719 33800290
    [Google Scholar]
  118. Gasse P. Mary C. Guenon I. IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J. Clin. Invest. 2007 117 12 3786 3799 10.1172/JCI32285 17992263
    [Google Scholar]
  119. Huaux F. Liu T. McGarry B. Ullenbruch M. Phan S.H. Dual roles of IL-4 in lung injury and fibrosis. J. Immunol. 2003 170 4 2083 2092 10.4049/jimmunol.170.4.2083 12574379
    [Google Scholar]
  120. Firmal P. Shah V.K. Chattopadhyay S. Insight into TLR4-mediated immunomodulation in normal pregnancy and related disorders. Front. Immunol. 2020 11 807 10.3389/fimmu.2020.00807 32508811
    [Google Scholar]
  121. Kerksick C. Willoughby D. The antioxidant role of glutathione and N-acetyl-cysteine supplements and exercise-induced oxidative stress. J. Int. Soc. Sports Nutr. 2005 2 2 38 44 10.1186/1550‑2783‑2‑2‑38 18500954
    [Google Scholar]
  122. Kwon D.H. Cha H.J. Lee H. Protective effect of glutathione against oxidative stress-induced cytotoxicity in RAW 264.7 macrophages through activating the nuclear factor erythroid 2-related factor-2/heme oxygenase-1 pathway. Antioxidants 2019 8 4 82 10.3390/antiox8040082 30939721
    [Google Scholar]
  123. Hedblom A. Hejazi S.M. Canesin G. Heme detoxification by heme oxygenase-1 reinstates proliferative and immune balances upon genotoxic tissue injury. Cell Death Dis. 2019 10 2 72 10.1038/s41419‑019‑1342‑6 30683864
    [Google Scholar]
  124. Campbell N.K. Fitzgerald H.K. Dunne A. Regulation of inflammation by the antioxidant haem oxygenase 1. Nat. Rev. Immunol. 2021 21 7 411 425 10.1038/s41577‑020‑00491‑x 33514947
    [Google Scholar]
  125. Gozzelino R. Jeney V. Soares M.P. Mechanisms of cell protection by heme oxygenase-1. Annu. Rev. Pharmacol. Toxicol. 2010 50 1 323 354 10.1146/annurev.pharmtox.010909.105600 20055707
    [Google Scholar]
  126. Bedard K. Krause K.H. The NOX family of ROS-generating NADPH oxidases: Physiology and pathophysiology. Physiol. Rev. 2007 87 1 245 313 10.1152/physrev.00044.2005 17237347
    [Google Scholar]
  127. Cheresh P. Kim S.J. Tulasiram S. Kamp D.W. Oxidative stress and pulmonary fibrosis. Biochim. Biophys. Acta Mol. Basis Dis. 2013 1832 7 1028 1040 10.1016/j.bbadis.2012.11.021 23219955
    [Google Scholar]
  128. Kliment C.R. Oury T.D. Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis. Free Radic. Biol. Med. 2010 49 5 707 717 10.1016/j.freeradbiomed.2010.04.036 20452419
    [Google Scholar]
  129. Maniscalco W.M. Watkins R.H. Pryhuber G.S. Bhatt A. Shea C. Huyck H. Angiogenic factors and alveolar vasculature: Development and alterations by injury in very premature baboons. Am. J. Physiol. Lung Cell. Mol. Physiol. 2002 282 4 L811 L823 10.1152/ajplung.00325.2001 11880308
    [Google Scholar]
  130. Baker C.D. Abman S.H. Impaired pulmonary vascular development in bronchopulmonary dysplasia. Neonatology 2015 107 4 344 351 10.1159/000381129 26044102
    [Google Scholar]
  131. Lignelli E. Palumbo F. Myti D. Morty R.E. Recent advances in our understanding of the mechanisms of lung alveolarization and bronchopulmonary dysplasia. Am. J. Physiol. Lung Cell. Mol. Physiol. 2019 317 6 L832 L887 10.1152/ajplung.00369.2019 31596603
    [Google Scholar]
  132. Galambos C. Sims-Lucas S. Abman S.H. Histologic evidence of intrapulmonary anastomoses by three-dimensional reconstruction in severe bronchopulmonary dysplasia. Ann. Am. Thorac. Soc. 2013 10 5 474 481 10.1513/AnnalsATS.201305‑124OC 23987309
    [Google Scholar]
  133. Holzfurtner L. Shahzad T. Dong Y. When inflammation meets lung development—an update on the pathogenesis of bronchopulmonary dysplasia. Mol. Cell Pediatr. 2022 9 1 7 10.1186/s40348‑022‑00137‑z 35445327
    [Google Scholar]
  134. Balany J. Bhandari V. Understanding the impact of infection, inflammation, and their persistence in the pathogenesis of bronchopulmonary dysplasia. Front. Med. (Lausanne) 2015 2 90 10.3389/fmed.2015.00090 26734611
    [Google Scholar]
  135. Chaubey S. Thueson S. Ponnalagu D. Early gestational mesenchymal stem cell secretome attenuates experimental bronchopulmonary dysplasia in part via exosome-associated factor TSG-6. Stem Cell Res. Ther. 2018 9 1 173 10.1186/s13287‑018‑0903‑4 29941022
    [Google Scholar]
  136. Zhu W.D. Xu J. Zhang M. Zhu T.M. Zhang Y.H. Sun K. MicroRNA 21 inhibits lipopolysaccharide induced acute lung injury by targeting nuclear factor κB. Exp. Ther. Med. 2018 16 6 4616 4622 10.3892/etm.2018.6789 30542412
    [Google Scholar]
  137. Dane D.M. Cao K. Zhang Y-A. Inhalational delivery of induced pluripotent stem cell secretome improves postpneumonectomy lung structure and function. J. Appl. Physiol. 2020 129 5 1051 1061 10.1152/japplphysiol.00205.2020 32909918
    [Google Scholar]
  138. Anton K. Glod J. Tumor-secreted factors that induce mesenchymal stromal cell chemotaxis. In: Mesenc Stro Cells Tum Stro Modul. 2016 193 214
    [Google Scholar]
  139. Abele A.N. Taglauer E.S. Almeda M. Antenatal mesenchymal stromal cell extracellular vesicle treatment preserves lung development in a model of bronchopulmonary dysplasia due to chorioamnionitis. Am. J. Physiol. Lung Cell. Mol. Physiol. 2022 322 2 L179 L190 10.1152/ajplung.00329.2021 34878940
    [Google Scholar]
  140. Xu W. Jieda X. Wu Y. Safety, efficacy and bio-distribution analysis of exosomes derived from human umbilical cord mesenchymal stem cells for effective treatment of bronchopulmonary dysplasia by intranasal administration in mice model. Int. J. Nanomedicine 2025 20 2521 2553 10.2147/IJN.S501843 40034220
    [Google Scholar]
  141. Lithopoulos M.A. Strueby L. O’Reilly M. Pulmonary and neurologic effects of mesenchymal stromal cell extracellular vesicles in a multifactorial lung injury model. Am. J. Respir. Crit. Care Med. 2022 205 10 1186 1201 10.1164/rccm.202012‑4520OC 35286238
    [Google Scholar]
  142. da Silva A.V. Serrenho I. Araújo B. Carvalho A.M. Baltazar G. Secretome as a tool to treat neurological conditions: Are we ready? Int. J. Mol. Sci. 2023 24 22 16544 10.3390/ijms242216544 38003733
    [Google Scholar]
  143. Fathi I. Miki T. Human amniotic epithelial cells secretome: Components, bioactivity, and challenges. Front. Med. 2022 8 763141 10.3389/fmed.2021.763141 35083233
    [Google Scholar]
  144. Tung S. Delavogia E. Fernandez-Gonzalez A. Mitsialis S.A. Kourembanas S. Harnessing the therapeutic potential of the stem cell secretome in neonatal diseases. In: Semin Perinatol. Amsterdam, Netherlands Elsevier 2023 47 151730 10.1016/j.semperi.2023.151730
    [Google Scholar]
/content/journals/cscr/10.2174/011574888X373765250710105821
Loading
Unveiling the Healing Potential of Stem Cells: The Promising Role of Secretome Therapy in the Treatment of Pulmonary Degenerative Disorders-A Comprehensive Systematic Review
Bentham Science Publishers ; https://doi.org/10.2174/011574888X373765250710105821
/content/journals/cscr/10.2174/011574888X373765250710105821
/content/journals/cscr/10.2174/011574888X373765250710105821
Loading

Data & Media loading...

Supplements

PRISMA checklist is available as supplementary material on the publisher’s website along with the published article. Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Review Article
Keywords: systematic review ; secretome therapy ; pulmonary degenerative disorders ; Stem cells ; bronchopulmonary dysplasia ; idiopathic pulmonary fibrosis ; acute lung injury

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test